206 related articles for article (PubMed ID: 12731325)
21. Bladder cancer biomarkers: current developments and future implementation.
Alvarez A; Lokeshwar VB
Curr Opin Urol; 2007 Sep; 17(5):341-6. PubMed ID: 17762628
[TBL] [Abstract][Full Text] [Related]
22. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder.
Bhuiyan J; Akhter J; O'Kane DJ
Clin Chim Acta; 2003 May; 331(1-2):69-77. PubMed ID: 12691866
[TBL] [Abstract][Full Text] [Related]
23. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
[TBL] [Abstract][Full Text] [Related]
24. HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade.
Lokeshwar VB; Block NL
Urol Clin North Am; 2000 Feb; 27(1):53-61. PubMed ID: 10696245
[TBL] [Abstract][Full Text] [Related]
25. [Hyaluronic acid and hyaluronidase. 2 new bladder carcinoma markers].
Hautmann SH; Schroeder GL; Civantos F; Duncan RC; Gnann R; Friedrich MG; Hellstern A; Huland H; Soloway MS; Lokeshwar VB
Urologe A; 2001 Mar; 40(2):121-6. PubMed ID: 11315586
[TBL] [Abstract][Full Text] [Related]
26. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
27. Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests?
Pirtskalaishvili G; Konety BR; Getzenberg RH
Postgrad Med; 1999 Nov; 106(6):85-6, 91-4. PubMed ID: 10576004
[TBL] [Abstract][Full Text] [Related]
28. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
29. Can urinary biomarkers replace cystoscopy?
Maas M; Bedke J; Stenzl A; Todenhöfer T
World J Urol; 2019 Sep; 37(9):1741-1749. PubMed ID: 30283995
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
[TBL] [Abstract][Full Text] [Related]
31. Hematuria screening test for urinary bladder mucosal infiltration in cervical cancer.
Chuttiangtum A; Udomthavornsuk B; Chumworathayi B
Asian Pac J Cancer Prev; 2012; 13(10):4931-3. PubMed ID: 23244084
[TBL] [Abstract][Full Text] [Related]
32. Urinary markers of bladder carcinoma.
Dey P
Clin Chim Acta; 2004 Feb; 340(1-2):57-65. PubMed ID: 14734196
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity and specificity of urinary hyaluronic acid and hyaluronidase in detection of bladder transitional cell carcinoma.
Jamshidian H; Hashemi M; Nowroozi MR; Ayati M; Bonyadi M; Najjaran Tousi V
Urol J; 2014 Mar; 11(1):1232-7. PubMed ID: 24595930
[TBL] [Abstract][Full Text] [Related]
34. [The BTA stat test in the follow-up for bladder cancer].
Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
[TBL] [Abstract][Full Text] [Related]
35. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
[TBL] [Abstract][Full Text] [Related]
36. Screening for bladder cancer using urine-based tumor markers.
Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
Minerva Urol Nefrol; 2008 Dec; 60(4):247-53. PubMed ID: 18923361
[TBL] [Abstract][Full Text] [Related]
37. Urine markers for bladder cancer surveillance: a systematic review.
van Rhijn BW; van der Poel HG; van der Kwast TH
Eur Urol; 2005 Jun; 47(6):736-48. PubMed ID: 15925067
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.
Chahal R; Darshane A; Browning AJ; Sundaram SK
Eur Urol; 2001 Oct; 40(4):415-20; discussion 421. PubMed ID: 11713396
[TBL] [Abstract][Full Text] [Related]
39. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
Zuiverloon TCM; de Jong FC; Theodorescu D
Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
[TBL] [Abstract][Full Text] [Related]
40. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer.
Droller MJ
J Urol; 1998 Aug; 160(2):619-20. PubMed ID: 9679940
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
